COR MEDICAL VENTURE STUDIO
BRING YOUR IDEAS TO THE MARKET
We are partnering with surgeons / clinicians / inventors to bring their ideas to the market. We stand-up companies (independent LLC’s or Corporations) and accelerate them to the market through our product development consulting services and network of medical device partners.
We work with corporations, universities, healthcare entities and government institutions to find non-dilutive funding in order to preserve equity and incubate ideas.
We are a full service, hands-on team that provide our portfolio companies the needed strategic value, agility, and support to build and grow.
PORTFOLIO COMPANIES
AVIRA
OVERVIEW Avira Health is pioneering the next generation of breast pump technology through its wearable connected devices. It aims to uplift the mother-infant dyad during the life changing transition into motherhood and beyond.
STATUS In development for launch in the US markets.
MARKET $2.5B
DELTA ORTHOPEDICS
OVERVIEW Simple, easy-to-use hinge knee system significantly reducing morbidity in treating distal femoral fractures. Standardized technique can be integrated into major knee systems. Low COGS due to streamlined sizing, design, and instrumentation.
STATUS Seeking corporate partner or investors to complete 510(k) clearance & initial alpha launch. Completed cadaveric testing with fully functional implants and instrumentation, completed pre-submission FDA meeting, patent pending.
SURGEON TEAM Drs. Lowery Barnes, Simon Mears and Paul Edwards
MARKET $208M hinged knee market & $100M distal femoral fracture market. Significant pull-through from $9B total knee market.
MEDULOC
OVERVIEW Intermedullary fixation system for the treatment of small, long-bone fractures (fingers, hands, feet, clavicle, radius, fibula, and ulna). Superior fracture reduction, fixation and rotational stability with Nitinol implant cut to patient specific length. Minimally invasive, soft tissue sparing surgical approach.
STATUS Design-stable implant and instrument kit, completed pre-submission FDA meeting with clearly defined regulatory pathway, three issued patents in US and OUS with several additional pending.
SURGEON TEAM Drs. Josh Hustedt, Lloyd Champagne and Mel Rosenwasser
MARKET $372M addressable market that is quickly growing
OSHERU
OVERVIEW Ziplyft is the first minimally invasive surgery for lids. Traditional blepharoplasty surgery typically takes up to 60 minutes to perform, with Ziplyft the procedure will take about 10 minutes with less swelling and bruising. Allowing the patient to return to normal activities quicker.
STATUS Clinical launch in 2023
SURGEON TEAM Drs. Patricia Buehler and Knute Buehler
MARKET $3.71B and expected to rise over the next 5 years to $5.2B
_bmp.png)
OSTEAL THERAPEUTICS
OVERVIEW Novel therapeutic platform for treatment of orthopedic infection. Initial candidate is a drug/device combination system that resolves periprosthetic joint infection (PJI) in 7 days using local delivery of high concentration antibiotics via an implantable prosthesis.
STATUS Clinical stage – Phase 3 (Completed Phase II trial, 6 issued patents)
SURGEON TEAM Drs. Brian de Beaubien, Antonia Chen, Thorsten Gerhke, Javad Parvizi and Bryan Springer.
MARKET $1.8B+ initial addressable U.S. market for PJI plus significant pull-through business.
SAIL FUSION
OVERVIEW Robust spinal fixation system for the treatment of Sacro-Illiac (SI) joint dysfunction. Utilizes posterior, mini-open surgical approach. Provides direct visualization, superior decompression, and large grafting volume.
STATUS Complete seed round of funding. 510(k) clearance expected by Q3 2023. Two issued patents and several additional patents pending.
SURGEON TEAM Drs. Hyun Bae, Vikas Patel and Peter Whang
MARKET $150M SI Joint fusion market (2019) with CAGR of 16%
SENSOR THERAPEUTICS
OVERVIEW Wearable biofeedback and data recording devices for use in rehabilitation following musculoskeletal surgery
STATUS Early clinical evaluation of lead product for rotator cuff repair
SURGEON TEAM Drs. Heinz Hoenecke and Armand Hatzidakis
MARKET Orthopedic Rehabilitation, Industrial Injury, Exercise
OVERVIEW Multi-planar expandable interbody spinal fusion system. Low profile design for safe insertion. Restores height and sagittal balance. Expansion provides superior bone densification and reduces subsidence.
STATUS Currently supporting human clinical cases (510k cleared, Three issued patents).
SURGEON TEAM Drs. Robert Eastlack, James Bruffey and Maneesh Bawa
MARKET $2.3B global interbody fusion market by 2023 with lumbar fusion ~30% of total market.
SPINE INNOVATION
OVERVIEW Tesa Medical is a medical device company focused on improving patient outcomes through enabling rapid, precise soft tissue tensioning and fixation. Tesa’s patented technology system, CordaSet™, allows for the rapid tensioning and fixation of soft tissue thereby enabling physicians to mitigate downstream consequences that currently affect as many as 30% of patients.
Numerous studies have examined the etiology of ACL reconstruction and revision surgeries. Published studies have shown laxity to be an issue in 10-30% of cases. Tesa believes that some of these issues are due to limitations in current technology to enable the clinician to adjust the tension of the graft prior to permanent fixation.
STATUS Pre 510k, Design-stable implant and instruments, clearly defined regulatory pathway.
SURGEON TEAM Drs. Thomas Vail, Michael Dillingham, Joseph Donahue, Akbar Nawab and David Caborn
MARKET $2B world-wide, with the US market representing roughly $800M. The U.S ACL/PCL reconstruction device market size is estimated to reach $360M by 2026.
TESA MEDICAL
In addition to our portfolio companies that are well developed and close to FDA clearance and approval, Cor has a number of projects that are being screened in its New Product Pipeline. CONTACT US for more information on our seed stage projects.
For more information or to speak to someone regarding our Venture Studio, please complete the CONTACT FORM and note “Venture Studio” in the message field.